Corporate Presentation 2025

Corporate Presentation 2025

Unique, multi-use topical platform technology utilizing multiple mechanisms of actions

Pipeline addressing large medical and aesthetic dermatology market opportunities

Lead program with compelling Phase 2b clinical data for once-weekly topical treatment of acne

Xyngari

Acne - STAR-1 Phase 3 - Statistically Significant

• Once-weekly topical application

• Positive STAR-1 Phase 3 study

• STAR-2 Phase 3 study to begin in 2025

  Psoriasis - Positive Phase 1b Completed

• Inhibits inflammatory cytokines IL-17A & IL-17F in vitro

• Reduced lesion size after 8 weeks

  DMT410

  Hyperhidrosis - Phase 2a planned with DAXXIFY

• Phase 1 POC completed with BOTOX

• Topical delivery of botulinum toxin to the dermis

• 75% reduction in gravimetric sweat production

  Aesthetics - Phase 1b PoC Completed

• Clinical improvement in aesthetic appearance seen

  • Pore Size

  • Fine Lines

  • Melasma

  • Sebum production

Senior Management

Gerry Proehl

Chairman, President, and CEO

Kyri Van Hoose, C.P.A., MBA

SVP, Chief Financial Officer

Maria Bedoya Toro Munera, Ph.D.

SVP, Regulatory Affairs & Quality Assurance

Chris Nardo, M.P.H., Ph.D.

SVP, Chief Development Officer

Board of Directors

Gerry Proehl Wendell Wierenga Ph.D. Steven J. Mento, Ph.D.

Andrew Sandler, M.D.

David Hale

Kathleen Scott

Mary Fischer Brittany Bradrick

Xyngari/DMT410 - Acne

US Prevalence ~50M

Market Size ~$2.3B2

DMT410 - Aesthetics

~13.1M(procedures)

DMT410 - Hyperhidrosis

Opportunity Highlights

85% of teenagers experience some form of acne1

Few new novel topical treatment options

• Most new products are reformulations and dosed QD or BID

  Almost 9.5 million procedures with neuromodulators3

• Average cost of one session is

  $4353

• Untapped markets where neuromodulators are rarely used

  BOTOX® injections expected to be 40% of the overall market.

  Growing demand for hyperhidrosis treatments, especially with increasing disease awareness

  1. - Guideline for Care and Management of Acne

  2. - IQVIA, Inc. Top Line Market and Sales Analysis from years 2015-2020

  3. - 2023 Plastic Surgery Statistics Report

  4. - GlobalData Axillary Hyperhidrosis: opportunity Assessment and Forecast to 2030 5- Stifl Dermatology Healthcare Market Overview